Navigation Links
QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
Date:4/11/2011

MOUNTAIN VIEW, Calif., April 11, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US. Data published in the peer-reviewed journal provided an in-depth look at weight loss and improvements in the full spectrum of co-morbidities studied as secondary endpoints, including cardiovascular, metabolic and inflammatory risk factors.

"Obesity is a serious medical condition associated with increased mortality from cardiovascular diseases, diabetes, cancer and other diseases, yet there is a lack of treatment options for the one-third of American adults who are obese," said Kishore Gadde, MD, director of obesity clinical trials at Duke University and lead investigator. "Half the patients in the study had at least three co-morbidities including diabetes, representing a population with the greatest medical need for weight loss. We observed significant weight loss, improvements in co-morbidities and a reduction in the need for concomitant medications in patients treated with QNEXA."

Specific results for all patients through 56 weeks as published in The Lancet are as follows:

Weight Loss

  • Average weight loss for QNEXA patients who completed the CONQUER study on the study drug was 28 pounds and 22 pounds with top-dose QNEXA and mid-dose QNEXA, respectively, compared to 4 pounds in the placebo group;
  • In the ITT-LOCF analysis, least-squares mean percent weight loss at week 56 was -7.8%* and -9.8%*, respectively, for the mid and top dose as compared to -1.2% for the placebo group;
  • Categorical weight loss from baseline (ITT-LOC
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
    2. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    3. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    5. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
    9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/26/2015)... , March 26, 2015 ... announced the addition of the "Global Smart ... report to their offering.      (Logo: ... Wearable Healthcare Devices and Services market to grow ... 2015-2019 The report covers the present ...
    (Date:3/26/2015)... 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" ... patent acceptance notice from the Israeli patent office with ... or reduce tissue damage caused by an increase in ... vessels are opened after a blockage causing a heart ... Damage can be caused to the heart ...
    (Date:3/26/2015)... N.J. , March 26, 2015  Becton, Dickinson ... that it will commence offers to exchange all validly ... by CareFusion Corporation, a wholly owned subsidiary of BD, ... in the table below. A Registration Statement on Form ... the New Notes was filed with the Securities and ...
    Breaking Medicine Technology:Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5
    ... samples to be used to identify molecular,signature of ... ALS Therapy,Development Institute (ALS TDI) announced today ... samples collected through an expanded network,of clinical partnerships. ... effort to indentify the altered expression of genes,and ...
    ... Vical Incorporated,(Nasdaq: VICL ) today ... a leading European medical university, and the ... governmental expert agency, to,evaluate Vical,s Vaxfectin(R) adjuvant ... Medical Technologies Inc.,OTCBB:BJCT) for a multivalent preventive ...
    Cached Medicine Technology:ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5
    (Date:3/26/2015)... MALVERN, PA (PRWEB) March 26, 2015 ... leading providers of continuing medical education, the ... for Culinary Medicine at Tulane University are ... in Culinary Medicine. The interdisciplinary program ... Specialist (CCMS) credential, is designed for physicians, nurse ...
    (Date:3/26/2015)... “The SWEET Act is an important step to ... and help parents who are working to reduce sugar in ... to support public health, and we will continue to stand ... of all families,” said Dr. Jane Delgado President and CEO ... of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman Rosa ...
    (Date:3/26/2015)... Saving Moses is a global humanitarian ... needed but least available. As one of their staple ... in the Benguela province of Angola to treat babies ... visit to their clinics, staff employed the art of ... babies in a nation the The New York Times ...
    (Date:3/26/2015)... Frencisco, CA (PRWEB) March 26, 2015 ... Center are proud to announce expanded offerings for Bay ... San Francisco Dental Implant Center has long been a ... have expanded its offerings to meet the strong demand ... in our reputation as a top-rated dental implant facility ...
    (Date:3/26/2015)... San Juan Capistrano, Calif. (PRWEB) March 26, 2015 ... monitoring equipment and repairs, is pleased to be featured ... the Discovery Channel on March 18, 2015. The ... status, and it is live on the Pacific Medical ... families that face life threatening emergencies, it is reassuring ...
    Breaking Medicine News(10 mins):Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Saving Moses Utilized Photography in an Effort to Engage Mothers and Their Babies on a Recent Visit to Angola 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3
    ... But Canadian study finds increase in non-serious side effects ... contain compounds called cannabinoids from the marijuana plant don,t ... associated with an increase in some non-serious side effects, ... in Montreal and the University of British Columbia (UBC) ...
    ... its wholly-owned subsidiary Embryome Sciences, Inc. announced ... International Embryome Initiative, an international collaboration with ... first systematic map of all the cell ... In a paper published today titled “The ...
    ... cellular ... analysis capabilities, ... a leader in innovative solutions for drug discovery and ... (Sunnyvale, CA) for $13 million. The acquisition,of Blueshift Biotechnologies, ...
    ... latest,report by the American Lung Association, Lung Disease Data, ... death rates due to other,leading causes of death such ... pulmonary disease (COPD) is expected to,become the third leading ... Association publishes Lung Disease Data to serve as a,resource ...
    ... Accelera Recognised as Key Partner in the Development of ... treatment of African,trypanosomiasis, commonly known as "sleeping sickness", by ... business unit of,Nerviano Medical Sciences (NMS), is to be ... The award will be conferred today in New York, ...
    ... Community in Hydration and Sanitation, Sand Bag , ... ... students assisted Missouri community residents who were impacted by raging ... students ensured that Clarksville families were educated on proper sanitation, the ...
    Cached Medicine News:Health News:Drugs With Marijuana Compounds Don't Boost Adverse Events 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 3Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 4Health News:MDS Analytical Technologies Acquires Blueshift Biotechnologies 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 3Health News:The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness" 2Health News:Sanford-Brown College Students Help in Missouri Flood Relief 2
    ... is part of a series of modular systems ... from 3.5 to 8.0 mm. Matching a combination ... provides convenience and flexibility for the orthopaedic surgeon ... may be customized using two of three screw ...
    The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
    ... a complete system of surgical instruments and ... fusion surgery. The system was designed in ... research and engineering with advanced materials, techniques ... different, and because the anatomy of the ...
    ... The Retrograde Humeral Nail enables fixation ... shoulder symptoms that may be associated with ... enables proximal and distal interlocking using a ... for posterior-anterior interlocking with the patient in ...
    Medicine Products: